Our simulations showed that IRHY became resistant to Tamiflu due to the loss of key hydrogen bonds between the drug and residues in a part of the NA’s structure known as the ’150-loop’
Computer chips of a type more commonly found in games consoles have been used by scientists at the University of Bristol to reveal how the flu virus resists anti-flu drugs such as Relenza and Tamiflu. Professor Adrian Mulholland and Christopher Woods from Bristol's School of Chemistry , together with colleagues in Thailand, used graphics processing units (GPUs) to simulate the molecular processes that take place when these drugs are used to treat the H1N1-2009 strain of influenza - commonly known as 'swine flu'. Their results, published today [29 May] in Biochemistry, provide new insight that could lead to the development of the next generation of antiviral treatments for flu. H1N1-2009 is a new, highly adaptive virus derived from different gene segments of swine, avian, and human influenza. Within a few months of its appearance in early 2009, the H1N1-2009 strain caused the first flu pandemic of the 21st-century. The antiviral drugs Relenza and Tamiflu, which target the neuraminidase (NA) enzyme, successfully treated the infection but widespread use of these drugs has led to a series of mutations in NA that reduce the drugs' effectiveness. Clinical studies indicate that the double mutant of swine flu NA known as IRHY2 reduced the effectiveness of Relenza by 21 times and Tamiflu by 12,374 times - that is, to the point where it has become an ineffective treatment.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
